793 / 1224
/
Matthias Guckenberger - SBRT for stage I NSCLC
51
Stereotactic ablative radiotherapy versus lobectomy for operable
stage I non-small-cell lung cancer: a pooled analysis of two
randomised trials
Chang
Lancet Oncol 2015
Discussion of this study:
Opponent
Supporter
Only 58 centers
Two high quality studies
Overall 38 centres
Best of-ist-time Tx in both studies
Differences in study design
Interpretation considering statistical
limitations
Surgical OS 67% in STARS and 100% in
ROSEL
Best evidence available until today
SBRT is better tolerated treatment resulting is most likely
identical overall survival
Higher toxicity versus higher rates of locoreginal recurrence